Watch Complete Prescribing Information and facts OPDIVO® (nivolumab) is indicated for that treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed immediately after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or even more lines of systemic therapy th